Special Issue

Antibiotic Treatment for Pseudomonas aeruginosa and Treatment Regimens

Message from the Guest Editor

Pseudomonas aeruginosa is a prevalent opportunistic pathogen that causes various infections in human. It is intrinsically resistant to a variety of antibiotics. Biofilm formation drastically increases the resistance, and persister cells are phenotypic variants that are highly recalcitrant to lethal doses of antibiotics. Mutations and horizontal acquisition of resistant genes further broaden the resistance spectrum and increase the level of resistance. Therefore, it is critical to understand the mechanisms of antimicrobial resistance and the development of resistance. Novel antimicrobials and treatment strategies are urgently needed. This Special Issue welcomes manuscripts describing the study of resistance mechanisms, development of resistance, identification of novel treatment targets and antimicrobials as well as strategies to increase treatment efficacies and repress the evolution of resistance in *P. aeruginosa*. **Keywords:** Pseudomonas aeruginosa; antibiotic resistance; novel antimicrobials; treatment strategies

Guest Editor

Prof. Dr. Weihui Wu

State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, Department of Microbiology, College of Life Sciences, Nankai University, Tianjin 300071, China

Deadline for manuscript submissions

closed (31 March 2023)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/99874

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

